Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center and Prospective Clinical Study of Orelabrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

NCT05097443 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT05097443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05097443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center and Prospective Clinical Study of Orelabrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
April 15, 2021
Completion date
December 31, 2024
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell nonhodgkin lymphoma, diffuse large b-cell lymphoma, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, mantle cell lymphoma